NeoGenomics reported third-quarter 2026 revenue of $209 million, up 11% from a year earlier, and a GAAP net loss of $8 million, down from $27 million. The company raised its full-year 2026 revenue and adjusted EBITDA guidance and narrowed its net loss outlook, and it said CEO Tony Zook will move to Executive Chairman as Warren Stone becomes CEO on January 4, 2027.
Q3 2026 revenue was $209 million, up 11%; clinical revenue was $195 million, up 13%, with NGS revenue up 29%.
Q3 2026 GAAP net loss was $8 million, compared with $27 million in Q3 2025; adjusted EBITDA was $19 million, up 53%.
Updated FY 2026 revenue guidance is $807 million to $809 million, up from $802 million to $806 million; adjusted EBITDA guidance is approximately $60 million, up from $56 million to $58 million.
Warren Stone, currently President and COO, will become CEO and a Board member effective January 4, 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
From NeoGenomics Laboratories, Inc.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$727.33M
+10.1%
$-0.84
—
-14.9%
FY2024
$660.57M
+11.6%
$-0.62
—
-11.9%
FY2023
$591.64M
+16.1%
$-0.70
—
-14.9%
FY2022
$509.73M
+5.2%
$-1.16
—
-28.3%
FY2021
$484.33M
+9.0%
$-0.07
-275.0%
-1.7%
Frequently asked questions
When is NeoGenomics Laboratories's next earnings date?
NeoGenomics Laboratories has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did NeoGenomics Laboratories earn last quarter?
For the quarter ended Sep 2026, NeoGenomics Laboratories reported diluted EPS of $-0.06 on revenue of $209.25M (+11.4%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.